Kramer BK, Hauske SJ, Chilton R, Mann JFE, et al. Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes. J Diabetes Complications 2023;37:108588.
PMID: 37633072